Metabolic psychiatry is making headlines. Harvard-affiliated McLean Hospital received a $20 million grant to establish the McLean Center for Metabolic Psychiatry, and Stanford psychiatrist Shebani Sethi, MD, has been reported as a favored candidate to lead the National Institute of Mental Health.
What does this mean for patient care today? We can already identify and treat metabolic problems in our patients. What we’re still learning is whether doing so can also improve psychiatric symptoms, and which patients are most likely to benefit.
The ketogenic diet has attracted much of the early attention, but metabolic psychiatry extends well beyond dietary interventions. Drawing on endocrinology, neuroscience, psychiatry, and immunology, the field explores how systemic metabolic health, brain energy metabolism, and immune signaling contribute to psychiatric illness.
Whole-body metabolic health
People with severe mental illness can face a 10- to 20-year reduction in life expectancy, with cardiometabolic disease accounting for much of the excess mortality. (1,2) For years, much of our work with metabolism in psychiatry has focused on preventing and managing medication-associated weight gain and changes in glucose and lipids. Metabolic abnormalities can also be present early in the illness. In a 2017 JAMA Psychiatry meta-analysis, Pillinger and colleagues found higher fasting insulin, greater insulin resistance, and poorer glucose tolerance in people with first-episode schizophrenia who had little or no prior antipsychotic exposure. (3)
In their 2026 review, Sethi and colleagues describe a bidirectional relationship between metabolic health and psychiatric illness. Conditions such as insulin resistance, type 2 diabetes, dyslipidemia, and obesity may influence psychiatric risk and illness course. Psychiatric illness may, in turn, contribute to metabolic deterioration through sleep disruption, altered stress responses, inflammation, and medication effects. (4,5)
Brain energy metabolism and immune signaling
Brain energy metabolism. The brain uses glucose and can also use ketones as fuel. At McLean Hospital, Du and colleagues used phosphorus magnetic resonance spectroscopy to examine how the brain buffers its energy supply. They found that the frontal-lobe creatine kinase reaction rate was 22% lower in participants with chronic schizophrenia than in healthy controls. Creatine kinase helps replenish ATP when energy demand rises. The finding raises a clinical question. Could changing how the brain manages its energy supply improve symptoms or functioning? (6)
Immune and metabolic signaling. Inflammation and metabolic dysfunction may help explain why patients with the same psychiatric diagnosis can have different underlying biology. In the Netherlands Study of Depression and Anxiety, Lamers and colleagues found that depressive symptoms characterized by increased appetite, weight gain, hypersomnia, and low energy were associated with higher inflammatory and metabolic syndrome scores, with associations persisting over six years. These findings suggest that particular symptom patterns may help identify patients with underlying immunometabolic dysfunction. In a separate randomized trial, Raison and colleagues found no overall antidepressant benefit from infliximab in treatment-resistant depression. An exploratory analysis suggested that the effect might vary with baseline inflammation. Could a patient’s inflammatory and metabolic profile help us predict treatment response? That remains to be established prospectively. (7,8)
Pharmacologic approaches
As researchers explore these biological differences, attention is turning to whether treatments targeting metabolic pathways might improve psychiatric outcomes.
Metformin is already used to address antipsychotic-associated weight gain. The small TRIO-BD trial examined a different use in patients with insulin resistance and treatment-resistant bipolar depression. At 14 weeks, 50% of participants taking metformin no longer met the study’s criteria for insulin resistance, compared with 4% taking placebo. Participants whose insulin resistance reversed also had greater improvements in depression and anxiety. (9,10)
GLP-1 receptor agonists have shown their clearest benefits for weight and glucose regulation. Liraglutide improved both in a trial of patients taking clozapine or olanzapine. A separate trial in adults with stable bipolar disorder and overweight or obesity also found reduced binge-eating symptoms. (11,12)
Pioglitazone, an insulin-sensitizing medication, improved depressive symptoms when added to citalopram in one small trial of major depression. A separate placebo-controlled trial in bipolar depression found no benefit. (13,14)
Nonpharmacologic approaches
Intermittent fasting. In a small eight-week randomized trial in older adults with insulin resistance, Kapogiannis and colleagues compared a 5:2 intermittent fasting regimen with a healthy eating plan. Both groups improved on several measures of brain metabolism, and the fasting group showed greater gains on some tests of executive function. Whether fasting improves psychiatric symptoms remains an open question. (15)
Ketogenic metabolic therapy. A very low-carbohydrate, high-fat diet induces nutritional ketosis, making ketones available to the brain as an additional fuel. A recent meta-analysis found small to moderate improvements in depressive symptoms in randomized trials, with less conclusive evidence for anxiety. (16)
Sethi and colleagues reported improvements in metabolic health and psychiatric symptoms in a small, uncontrolled pilot involving adults with bipolar disorder or schizophrenia. In a separate 2026 randomized trial of 88 adults with treatment-resistant depression, both diet groups improved substantially. The ketogenic group improved by about two additional points on the PHQ-9 at six weeks. The between-group difference was no longer statistically significant at 12 weeks. We’re still learning which patients are most likely to benefit and whether those gains last. (17,18)
Exercise. Exercise has a larger body of clinical evidence, especially for depression. A 2024 BMJ analysis of 218 randomized trials found that walking or jogging, strength training, and yoga reduced depressive symptoms. The Nature Mental Health review also describes potential benefits for attention in ADHD and for cognition and daily functioning in schizophrenia. (19,4)
At Psychiatry Redefined, we’ve long emphasized a precision model that uses testing to determine each patient’s nutrient needs and address them to optimize brain function. This work dovetails with metabolic psychiatry. We would argue, though, that there is no single diet or treatment that’s right for everyone. The work is to understand the biology of the person in front of us and use that understanding to guide treatment. The broader field of metabolic psychiatry gives us much to learn and new reasons to hope for better outcomes for our patients.
Ready to learn personalized metabolic strategies to help your patients? Learn how the Fellowship in Functional Psychiatry can help you tackle complex cases and improve care. Schedule a private call now to get started.
References
- Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: A meta-review. World Psychiatry. 2014;13:153–160.
- Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe mental illness. Nat Rev Cardiol. 2021;18:136–145.
- Pillinger T, Beck K, Gobjila C, et al. Impaired glucose homeostasis in first-episode schizophrenia: A systematic review and meta-analysis. JAMA Psychiatry. 2017;74(3):261–269.
- Sethi S, Berk M, Andreazza AC, et al. Metabolic psychiatry targeting metabolic dysregulation in mental health. Nat Ment Health. 2026;4(4):508–520.
- Nousen EK, Franco JG, Sullivan EL. Unraveling the mechanisms responsible for the comorbidity between metabolic syndrome and mental health disorders. Neuroendocrinology. 2013;98:254–266.
